A Phase 3 Multinational, Randomized, Double- Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy
|Effective start/end date||6/1/22 → 11/1/22|
- SAREPTA THERAPEUTICS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.